Effect of sodium–glucose cotransporter-2 inhibitors on aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational study

Table 1 Evaluation before and after sodium–glucose cotransporter-2 inhibitor administration

	before	after	p-value
Body weight, kg	77.3 ± 18	76.0 ± 18	< 0.001
Body mass index, kg/m²	29.4 ± 5.5	28.9 ± 5.3	< 0.001
Systolic blood pressure, mmHg	130 ± 13	127 ± 13	N.S.
Diastolic blood pressure, mmHg	80 ± 10	77 ± 9	< 0.05
Heart rate, bpm	81 ± 12	76 ± 11	< 0.01
Hematocrit, mg/dL	42.4 ± 3.7	43.9 ± 3.6	N.S.
Serum creatinine, mg/dL	0.73 ± 0.18	0.76 ± 0.19	< 0.05
Estimated glomerular filtration rate, mL/min/1.73m²	81.3 ± 21.3	78.9 ± 21.1	N.S.
Serum potassium, mEq/L	4.1 ± 0.3	4.2 ± 0.3	N.S.
Fasting plasma glucose, mg/dL	157 ± 52	133 ± 29	< 0.01
HbA1c, %	8.1 ± 1.3	7.5 ± 1.0	< 0.001
Plasma renin activity, ng/mL/h	2.8 ± 3.0	3.5 ± 3.7	N.S.
Plasma aldosterone concentration, pg/mL	144 ± 127	155 ± 100	N.S.
Aldosterone-to-renin ratio	90.9 ± 51.6	81.4 ± 62.9	N.S.

Abbreviations: BW body weight, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HR heart rate, Ht hematocrit, s-Cr serum creatinine, eGFR estimate glomerular filtration rate, s-K serum potassium level, FPG fasting plasma glucose, HbA1c hemoglobin A1c, ARR aldosterone-to-renin ratio, PRA plasma renin activity, PAC plasma aldosterone concentration, ARR aldosterone to renin ratio, N.S. not significant
Data are n (%) or mean ± SD

ISSN: 1472-6823